Exciting news!
HAMLET BioPharma has signed a Letter of Intent with a German uro-oncology partner on a potential collaboration for Alpha1H in bladder cancer. Alpha1H has FDA Fast Track and clearance for a pivotal Phase III study. 🧬🤝
Read more: https://t.co/ftrBIHFD7q
🎉Our Founder, Prof. Catharina Svanborg, is featured in @FemestMag, sharing HAMLET BioPharma's story and our journey from discovery to clinic.
Plus: new highlights on novel non-antibiotic infection therapies presented at @biozentrum Basel.
Read more: https://t.co/7QnsT1mQCi
🗞️📊Please see Hamlet BioPharma’s Q2 Interim Report (Oct–Dec 2025).
We highlight the exciting progress we’ve made and are focused on what’s ahead:
🔗 Link to the press release: https://t.co/DxwYOgFN8z
🚨The leading international journal Nature Microbiology has published our latest paper! 🧬
Title -
Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.
🔗 Article link: https://t.co/62ICeHCN81
🎯 Major milestone: Hamlet BioPharma receives FDA feedback supporting a pivotal study for Alpha1H, our first-in-class therapy for early-stage bladder cancer.
Read more 👉https://t.co/AdlCXoFIxW
#FDA#CancerResearch#Oncology#Biotechnology#ClinicalTrials